-
TSUMURA & CO.
- Stock Code：
-
4540
- Market：
-
TSE Prime
- Sector：
-
Pharmaceutical
Print
Stock Price Index
2024/05/09 15:00
- Close Price
3,692.0
- Change
-58.0
-1.55
%
- Volume
463,100
| Price/Book
|
0.95
|
| Forward P/E
|
9.94
|
| Forward Div Yield
|
3.68%
|
| Market Cap
|
283.3B
|
Company Profile
Beginning with its founding in 1893, the Tsumura Group core business has been the manufacture and sales of pharmaceuticals made from crude drugs derived from plants and other natural products, and our share of the domestic prescription Kampo formulation market exceeds 80%.
In addition to steady growth in our domestic business, we have begun full-scale business in China since 2017 and have been building a business foundation to become a medium- to long-term growth driver. Through our business in China, we aim to contribute to develop the Chinese traditional medicine industry.
In our long-term management vision for 2031, “TSUMURA VISION “Cho-WA” 2031”, we aim to contribute to well-being through evidence-based provision of Kampo and traditional Chinese treatments and other products and services tailored to the individual’s life stage, symptoms, genetic makeup and living environment.
Major Shareholders
As of March 31,2023
| 1
|
The Master Trust Bank of Japan, Ltd. (Trust Account)
|
12,215
|
15.96
|
| 2
|
Bank of China (Hong Kong) Limited / Ping An Life Insurance of China, Ltd.
|
7,675
|
10.03
|
| 3
|
Custody Bank of Japan, Ltd. (Trust Account)
|
3,622
|
4.73
|
| 4
|
The Bank of New York Mellon (International) Limited 131800
|
2,720
|
3.56
|
| 5
|
The Bank of Tokyo-Mitsubishi UFJ, Ltd.
|
2,197
|
2.87
|
| 6
|
State Street Bank and Trust Company 505001
|
2,156
|
2.82
|
| 7
|
Stock held by Tsumura Group employees
|
1,772
|
2.32
|
| 8
|
Bright Ride Limited
|
1,692
|
2.21
|
| 9
|
The Bank of New York Mellon 140051
|
1,539
|
2.01
|
| 10
|
JP Morgan Chase Bank 380634
|
1,397
|
1.83
|
*Note:The shareholding ratio is calculated excluding 229,532 shares of treasury stock.
The above treasury stock does not include 137,800 shares of treasury stock held as trust assets of the executive compensation the Board Incentive Plan Trust.
Current Share Status
|
|
FY2022
|
| Japanese financial institutions
|
30.02%
|
| Japanese securities firms
|
1.48%
|
| Other Japanese corporations
|
7.47%
|
| Foreign institutions
|
46.67%
|
| Japanese individuals and others
|
14.36%
|
Perfomance and Financial Summary
Profitability & Solvency Index
Ratio to total sales
| ■
|
Domestic business：Prescription Kampo Products
|
85.2%
|
| ■
|
Domestic business：OTC Kampo etc.
|
2.8%
|
| ■
|
Domestic business：Other
|
1.0%
|
| ■
|
China business
|
11.0%
|
Consolidated operating results
[M.JPY]
| Net sales
|
116,413
|
129,546
|
140,043
|
| Domestic business
|
-
|
-
|
124,698
|
| China business
|
-
|
-
|
15,345
|
| Operating profit
|
19,382
|
22,376
|
20,916
|
| Domestic business
|
-
|
-
|
21,190
|
| China business
|
-
|
-
|
-273
|
| Ordinary profit
|
20,866
|
25,904
|
23,453
|
| Profit attributable to owners of parent
|
15,332
|
18,836
|
16,482
|
| Profit per share
|
200.4
|
246.2
|
215.6
|
Consolidated financial condition
[M.JPY]
| Total assets
|
319,063
|
350,981
|
396,813
|
| Net assets
|
233,169
|
258,109
|
272,246
|
| Investments
|
-
|
12,095
|
14,679
|
| Depreciation
|
8,210
|
8,743
|
10,101
|
| Personnel expenses
|
32,294
|
32,902
|
34,244
|
| R&D expenses
|
6,631
|
7,313
|
7,594
|
| Advertising expenses
|
829
|
1,104
|
1,026
|
| Basic earnings per share
|
2,846.58
|
3,133.97
|
3,299.42
|
| Equity-to-asset ratio
|
68.3
|
68.3
|
63.5
|
Cash Flows
[M.JPY]
| Cash flows from operating activities
|
16,102
|
21,314
|
16,452
|
| Cash flows from investing activities
|
-7,352
|
-9,111
|
-15,493
|
| Cash flows from financing activities
|
-10,425
|
-8,181
|
24,423
|
※The Company has applied the Accounting Standard for Revenue Recognition from the beginning of the FY2021.
＊Investments: investments in property, plant and equipment and software.
copyright© StockWeather.com,Inc. All Rights Reserved.
